COVID-19 Update. Learn More

Risankizumab (trade name Skyrizi) effective for plaque psoriasis – MD Magazine

nurse working in medical laboratory. Model signs the model release

Long-term results from the phase 3 IMMhance study of risankizumab (Skyrizi) in patients with psoriasis indicated that a significant number of patients receiving risankizumab maintained complete skin clearance at week 94.

“Results show that Skyrizi has the potential to provide long-term relief from the signs and symptoms of psoriasis,” said Marek Honczarenko, MD, PhD, vice president, immunology development, AbbVie.

In this study, patients who reached a score of clear or almost clear on the static Physician Global Assessment (sPGA 0/1) at week 28 were randomized to either continue on risankizumab or placebo. Of those with continuous treatment with risankizumab, 73% achieved a sPGA of 0 and 72% reached a 100% improvement in the Psoriasis Area and Severity Index (PASI 100).

Read more about the study.


Thinking of visiting Toronto’s premier skin clinic soon?

Fill out the inquiry form below and let us know your area of interest.

  • Optional

Call us today @ 416.633.0001